Saponin QS-21 adjuvants in cancer vaccines Book Section
| Authors: | Ragupathi, G.; Gardner, J. R.; Gin, D. Y.; Livingston, P. O. |
| Editors: | Rappuoli, R.; DeGregorio, E. |
| Article/Chapter Title: | Saponin QS-21 adjuvants in cancer vaccines |
| Abstract: | Despite the fact that approximately half of all vaccines approved for human use in the USA use an adjuvant, few of the adjuvants approved for clinical use have more than marginal activity. In both the infectious disease and cancer settings, the immunological adjuvant selected is critically important and in both settings, saponin adjuvants such as QS-21 and those that contain QS-21 have proven to be among the most potent. Despite challenges in production, quality control, stability and toxicity, QS-21 has exhibited exceptional adjuvant properties with a range of antigens as both a standalone adjuvant and a component in adjuvant mixtures. QS-21 is able to augment antibody and T-cell responses against antigens associated with a variety of infectious diseases, degenerative disorders and cancers. The recent synthesis of QS-21 has provided a robust method to produce this leading vaccine adjuvant in high purity as well as to produce novel synthetic QS-21 congeners designed to induce increased immune responsiveness with decreased toxicity. © 2011 Future Medicine. All right reserved. |
| Book Title: | Novel Immunologic Adjuvants |
| ISBN: | 978-1-78084-102-1 |
| Publisher: | Future Medicine |
| Publication Place: | London, UK |
| Date Published: | 2011-10-01 |
| Start Page: | 55 |
| End Page: | 66 |
| Language: | English |
| DOI: | 10.2217/ebo.11.24 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 5 -- Export Date: 3 March 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
144Ragupathi -
41Gin -
228Livingston -
34Gardner
Related MSK Work